Background Cardiac allograft vasculopathy (CAV) remains a leading cause of morbidity and
mortality after orthotopic heart transplantation (OHT). Little is known about the influence of …

Background Early aspirin (ASA) use after orthotopic heart transplantation (OHT) has been
associated with lower rates of cardiac allograft vasculopathy (CAV). We hypothesized that …

Aim Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality after
heart transplantation (HT). Enhanced platelet reactivity is a contributing factor. We aimed to …

Background Enhanced platelet reactivity may play a role in cardiac allograft vasculopathy
(CAV) progression. The use of antiplatelet agents after heart transplantation (HT) has been …

Objectives: This study compared the prognosis of patients with proximal cardiac allograft
vasculopathy (CAV) treated with percutaneous intervention (PCI) to the prognosis of those …

Cardiac allograft vasculopathy (CAV) is a complex disease that remains a significant cause
of morbidity and mortality after orthotopic heart transplantation (OHT). Originating as a result …

Background Cardiac allograft vasculopathy (CAV) remains a major long-term complication
in heart transplant (HT) recipients related to increased mortality. We aimed to identify non …

BACKGROUND Long-term survival after heart transplantation (HTx) is compromised by
cardiac allograft vasculopathy (CAV) characterized by coronary macro-and microvascular …

We evaluated our quarter-century experience with percutaneous coronary intervention (PCI)
in patients with cardiac allograft vasculopathy (CAV). CAV is a progressive form of …

Background: Cardiac allograft vasculopathy (CAV) is a major contributor of heart transplant
recipient mortality. Little is known about the prototypes of CAV trajectories at the population …